Oropharyngeal Cancer

  • Siavash Jabbari
  • Kim Huang
  • Jeanne Marie Quivey


Approximately 8,500 cases/year in the US with male predominance (3:1). Etiologies include consumption of alcohol, tobacco, betal and areca nuts, and HPV infection. Recent decrease in the incidence of tobacco-related cancers. Recent increase in HPV-related incidence rates attributed to changing sexual practices. HPV-related cancers appear to occur at a slightly younger age and have better survival rates when treated with radiotherapy and chemotherapy as compared to non-HPV-related cancers. Second primary tumors in the upper aerodigestive tract and lung occur in ∼25% of patients due to risk factors and lifestyle.


Regional Lymph Node Metastasis Great Dimension Lateral Pterygoid Muscle Contralateral Lymph Node Preventive Dental Care 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.PubMedCrossRefGoogle Scholar
  2. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.PubMedCrossRefGoogle Scholar
  3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.PubMedCrossRefGoogle Scholar
  4. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368(9538):843-854.PubMedCrossRefGoogle Scholar
  5. Bourhis J, Sire C, Lapeyre M, et al. Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: Results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2008: 72(1 Supplement S): S31-S32.Google Scholar
  6. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.PubMedCrossRefGoogle Scholar
  7. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.PubMedCrossRefGoogle Scholar
  8. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26(4):612-619.PubMedCrossRefGoogle Scholar
  9. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.PubMedCrossRefGoogle Scholar
  10. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.PubMedCrossRefGoogle Scholar
  11. Eisbruch A, Levendag PC, Feng FY, et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S40-S42.PubMedCrossRefGoogle Scholar
  12. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.PubMedCrossRefGoogle Scholar
  13. Fakhry C, Westra WH, Sigui L, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved survival of patients with human Papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2009;100:261-269.CrossRefGoogle Scholar
  14. Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:231-241.PubMedCrossRefGoogle Scholar
  15. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987;10:19-30.PubMedCrossRefGoogle Scholar
  16. Langendijk JA, Bourhis J. Reirradiation in squamous cell head and neck cancer: recent developments and future directions. Curr Opin Oncol 2007;19(3):202-209.PubMedCrossRefGoogle Scholar
  17. Levendag PC, Teguh DN, Heijmen, BJ. Oropharynx. In: Perez CA, Brady LW, Halperin EC, et al., editors. Principles and practice of radiation oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. pp. 913-957.Google Scholar
  18. O’Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys. Oct 1 2001;51(2):332-343.Google Scholar
  19. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.Google Scholar
  20. Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S112-S114.PubMedCrossRefGoogle Scholar
  21. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. Jul 2009;92(1):4-14.PubMedCrossRefGoogle Scholar
  22. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-1715.PubMedCrossRefGoogle Scholar
  23. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006;64(5):1308-1316.PubMedCrossRefGoogle Scholar
  24. Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys 1991;20:21-28.PubMedCrossRefGoogle Scholar
  25. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-1704.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Siavash Jabbari
    • 1
  • Kim Huang
    • 1
  • Jeanne Marie Quivey
    • 1
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations